Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JALSG-APL220 phase II study of arsenic trioxide plus all-trans retinoic acid for newly diagnosed acute promyelocytic leukemia
jRCTs041200102Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide, tretinoin, idarubicin, methotrexate, cytarabine and 1 more in Acute promyelocytic leukaemia (APL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year event-free survival stratified by APL risk. Started Feb 2021; status: active, not recruiting.
02
Drugs
arsenic trioxidetretinoinidarubicinmethotrexatecytarabine
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs041200102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200102.